Dalfopristin
Synercid (dalfopristin) is a small molecule pharmaceutical. Dalfopristin was first approved as Synercid on 1999-09-21. It is used to treat bacterial infections, staphylococcal skin infections, and streptococcal infections in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Synercid
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dalfopristin
+
Quinupristin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNERCID | King Pharmaceuticals | N-050748 RX | 1999-09-21 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| synercid | New Drug Application | 2019-08-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| staphylococcal skin infections | EFO_1001849 | D013207 | L00 |
| streptococcal infections | EFO_1001476 | D013290 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2770 | Injection, quinupristin/dalfopristin, 500 mg (150/350) |
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Feeding behavior | D005247 | — | — | — | 1 | — | 1 | ||
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | 1 | — | 1 |
| Neurodevelopmental disorders | D065886 | F89 | — | — | — | 1 | — | 1 | |
| Attention deficit and disruptive behavior disorders | D019958 | HP_0010865 | F91.3 | — | — | — | 1 | — | 1 |
| Failure to thrive | D005183 | — | — | — | 1 | — | 1 | ||
| Treatment outcome | D016896 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | 2 | 1 | — | — | 3 | |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | 1 | — | — | 2 |
| Serotonin syndrome | D020230 | EFO_1001842 | — | 1 | 1 | — | — | 2 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | — | 2 |
| Leukemia | D007938 | C95 | — | 2 | — | — | — | 2 | |
| Myelodysplastic syndromes | D009190 | D46 | — | 2 | — | — | — | 2 | |
| Lymphoma | D008223 | C85.9 | — | 2 | — | — | — | 2 | |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Abdominal pain | D015746 | R10.9 | — | 1 | — | — | — | 1 | |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | — | — | 1 |
| Body weight changes | D001836 | — | 1 | — | — | — | 1 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | — | 1 |
| Myelodysplastic-myeloproliferative diseases | D054437 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
| Muscle spasticity | D009128 | HP_0001257 | — | — | — | — | 1 | 1 | |
| Paresis | D010291 | HP_0001269 | — | — | — | — | 1 | 1 | |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DALFOPRISTIN |
| INN | dalfopristin |
| Description | Dalfopristin is a macrolide that is pristinamycin IIA in which the double bond between positions 26 and 26a of the pyrroline ring has been reduced and position 26R carries a [2-(diethylamino)ethyl]sulfonyl group. It is a semi-synthetic streptogramin antibiotic and often used as a mixture with quinupristin for the treatment of vancomycin-resistant Enterococcus faecium. It has a role as an antibacterial drug and a protein synthesis inhibitor. It is a macrolide, a member of 1,3-oxazoles, a cyclic ketone, an enamide, a secondary alcohol, a secondary carboxamide, a tertiary carboxamide, a sulfone, a tertiary amino compound, a carboxylic ester and a macrolide antibiotic. It is functionally related to a pristinamycin IIA. |
| Classification | Small molecule |
| Drug class | steriodal compounds acting on progesterone receptors (excluding-gest- compounds); antibacterials, pristinamycin derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCS(=O)(=O)[C@@H]1CCN2C(=O)c3coc(n3)CC(=O)C[C@H](O)/C=C(C)/C=C/CNC(=O)/C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)[C@@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 112362-50-2 |
| RxCUI | 229369 |
| ChEMBL ID | CHEMBL1200937 |
| ChEBI ID | — |
| PubChem CID | 6323289 |
| DrugBank | DB01764 |
| UNII ID | R9M4FJE48E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,961 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
659 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more